---
title: "Understanding the Market | RemeGen rose nearly 5% as 10 research projects were showcased at ESMO, institutions optimistic about its accelerated overseas expansion"
description: "RemeGen's stock price rose nearly 5%, up 4.81% as of the time of publication, trading at HKD 96.95, with a transaction volume of HKD 706 million. The company presented 10 studies at the 2025 European "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261990795.md"
published_at: "2025-10-21T07:07:03.000Z"
---

# Understanding the Market | RemeGen rose nearly 5% as 10 research projects were showcased at ESMO, institutions optimistic about its accelerated overseas expansion

> RemeGen's stock price rose nearly 5%, up 4.81% as of the time of publication, trading at HKD 96.95, with a transaction volume of HKD 706 million. The company presented 10 studies at the 2025 European Society for Medical Oncology (ESMO) annual meeting, with the Phase III study data of Vadastuximab being published for the first time and set to be featured in the New England Journal of Medicine. Huatai Securities believes that the global competitiveness of the company's pipeline will accelerate overseas expansion, maintaining a "Buy" rating

According to Zhitong Finance APP, RemeGen (09995) rose nearly 5%, up 4.81% to HKD 96.95 as of the time of writing, with a transaction volume of HKD 706 million.

In terms of news, from October 17 to 21 local time, the 2025 European Society for Medical Oncology (ESMO) Annual Meeting will be held in Berlin, Germany. At this year's conference, RemeGen will showcase 10 major research studies. Among them, the Phase III study data of RC48-C016 using Vadastuximab for first-line treatment of urothelial carcinoma will be prominently announced for the first time at the conference chair forum and will be published in full online in the New England Journal of Medicine (NEJM). In addition, the Phase III clinical research data of Taitasib for the treatment of IgA nephropathy will be presented in the form of a "Late-Breaking Oral" report at the 2025 American Society of Nephrology (ASN) Annual Meeting, which will be held from November 5 to 9 in Houston, USA.

Huatai Securities believes that the intensive data readouts fully confirm the global competitiveness of the company's pipeline and are expected to accelerate its overseas expansion: 1) The overseas Phase III study of Vadastuximab is steadily advancing, and the firm expects the BLA for the 2LUC indication to be ready by early 2026; 2) RC148 has received CDEBTD, and the overseas Phase I/II clinical trial has been approved by the FDA, showing potential for overseas expansion; 3) The global Phase III enrollment of Taitasib MG is proceeding smoothly, and pSS is expected to become the next key indication. Maintain "Buy"

### Related Stocks

- [688331.CN - RemeGen](https://longbridge.com/en/quote/688331.CN.md)
- [09995.HK - REMEGEN](https://longbridge.com/en/quote/09995.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 榮昌生物提高了股票回購的價格上限 | 榮昌生物解除股票回購價格上限 | [Link](https://longbridge.com/en/news/272783447.md) |
| 交銀國際控股公司維持對榮昌生物有限公司 H 股（9995）的買入評級 | 在昨天發佈的一份報告中，交通銀行國際控股公司對榮昌生物（RemeGen Co. Ltd. Class H）維持了買入評級，目標價為 136.00 港元。聲明：享受 50% 的 TipRanks Premium 折扣，解鎖對沖基金級別的數據和 | [Link](https://longbridge.com/en/news/273178637.md) |
| 川普稱將訪委內瑞拉 但時間未定 | （法新社華盛頓 13 日電）美國總統川普今天表示，他計劃訪問委內瑞拉，並重申滿意委國臨時總統表現。川普今天告訴媒體「我將訪問委內瑞拉」，但目前尚未決定時間。美軍 1 月抓捕時任委內瑞拉總統馬杜洛（Nicolas Maduro）後，由原副總統 | [Link](https://longbridge.com/en/news/275981379.md) |
| 金價曾插水挫 4% 銀價瀉近 12% 分析：美股大跌觸發演算法沽貨 | 金價一度下挫 4.1%，銀價跌 11.7%，因美股大跌引發算法交易賣盤。金價現回穩至 4981.5 美元，銀價 77.13 美元。分析認為，市場對人工智慧影響盈利的擔憂加劇拋售，追加保證金通知也加重了流動性壓力。儘管近期大跌，多家機構仍看好 | [Link](https://longbridge.com/en/news/275847502.md) |
| 不敵川普施壓 蓋洛普停止追蹤總統支持率 | 美國蓋洛普宣佈停止追蹤總統支持率，結束自 1930 年代以來的慣例。此決定源於總統川普對民調機構的威脅，稱虛假民調應視為刑事犯罪。蓋洛普表示，此舉是基於自身研究目標的策略性調整，強調將繼續進行嚴謹的研究，關注重大議題。川普的支持率自去年以來 | [Link](https://longbridge.com/en/news/275756953.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.